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COVID-19-associated immune thrombocytopenia
Thrombocytopenia is a risk factor for increased morbidity
and mortality in patients infected with the new severe acute
respiratory syndrome coronavirus 2, SARS-CoV-2 (COVID-
19 infection).1 Thrombocytopenia in COVID-19 patients
may be caused by disseminated intravascular coagulation
(DIC), sepsis or be drug-induced. Recently a single case
report suggested immune thrombocytopenia (ITP) may be
associated with COVID-19 infection.2 ITP is a rare autoim-
mune disease characterised by a platelet count <100 9 109/l,
leading to an increased risk of bleeding.3 Several risk factors
have been described for ITP including environmental (e.g.
infection, malignancy and drugs) and genetic predisposition.4
We report here the first case series of three patients with ITP
associated with COVID-19 infection.
Patient 1 is a 59-year-old man, known for 10 years with a
stage IV neuroendocrine tumour (NET) of the small bowel,
who presented with oral mucosal petechiae and spontaneous
skin haematomas. He also experienced symptoms of cough-
ing and fever 10 days before presentation and his partner
had a documented COVID-19 infection. Full blood counts
showed an isolated thrombocytopenia (<3 9 109/l) without
signs of dysplasia in the peripheral blood film and he tested
positive for COVID-19 by polymerase chain reaction (PCR)
on a nasopharyngeal swab. Additional diagnostic procedures
showed no signs of NET progression or other infections
(Table I; Figure S1A, B). After excluding other causes of
thrombocytopenia, including DIC, bacterial sepsis and medi-
cation, he was diagnosed with COVID-19-associated ITP. He
was treated with platelet transfusion, without increment, fol-
lowed by intravenous immunoglobulins (IVIG) 1 g/kg for
two days. Platelet autoantibodies were tested positive. After
an increase to 47 9 109/l, platelet count dropped to
19 9 109/l when dexamethasone was started leading to a pla-
telet count of 51 9 109/l on day 27 (Fig 1A).
Patient 2, a 66-year-old woman with hypertension, pre-
sented with petechiae, spontaneous epistaxis and increased
blood loss from haemorrhoids since three weeks (Figure S2).
Four weeks before admission she experienced fever, dyspnoea
and coughing during a week, followed by diarrhoea and
vomiting for several days. On admission, oropharyngeal swab
PCR confirmed COVID-19 infection. Platelet counts at
admission were 2 9 109/l (Table I). Additional diagnostics
showed no signs of other infections, recent medication
changes or antiphospholipid antibodies. Autoantibodies to
platelets tested negative. One unit of platelets was adminis-
tered without increment. She was diagnosed with COVID-
19-associated ITP and treated with dexamethasone 40 mg
daily for four days. Without any response on day 6 patient
received IVIG resulting in a platelet count of 32 9 109/l on
day 22 (Fig 1B).
Patient 3, a 67-year-old man with a history of hyperten-
sion and diabetes mellitus, presented with fever, coughing
and dyspnoea since nine days. Blood counts were normal at
admission and his computed-tomography (CT) scan showed
bilateral infiltrates. He was diagnosed with COVID-19 by
PCR on oropharyngeal swab. Because of respiratory failure
he was transferred to the ICU at day 2 and intubated on day
3. On day 10 a CT scan was repeated due to lack of respira-
tory improvement, which showed segmental pulmonary
embolism for which he was treated with unfractionated hep-
arin. Platelet counts dropped from 112 9 109/l on day 10 to
3 9 109/l on day 12 (Fig 1C). His clinical condition as well
as other coagulation parameters remained stable and hep-
arin-induced thrombocytopenia was excluded (Table I). Lab-
oratory examination excluded pseudothrombocytopenia and
thrombotic thrombocytopenic purpura. Anticoagulant ther-
apy was continued with a target platelet count of >40 9 109/
l. Unfortunately, he did not have increments on platelet
transfusions and died of an intracerebral bleeding within
24 h. Based on the course of platelet counts and exclusion of
other causes we consider the thrombocytopenia as COVID-
19-associated ITP.
Viral infections are associated with ITP.4 Here we
describe the first case series of three patients with COVID-
19-associated ITP. The ITP occurred not only during active
COVID-19 infection, but also up to 10 days after the clini-
cal COVID-19 symptoms subsided. Diagnosis of COVID-
19-associated ITP may be difficult because of several other
potential causes, for instance the coagulation activation by
COVID-19 infection leading to DIC and subsequent throm-
bocytopenia. Also, treatments for COVID-19, including hep-
arin, azithromycin and hydroxychloroquine, may lead to
thrombocytopenia.1
The goal of ITP treatment is preventing severe bleeding by
providing a safe platelet count.3 Treatment for COVID-19-
associated ITP may pose several issues. Commonly used
treatments include IVIG, glucocorticoids or thrombopoietin
receptor agonists (TPO-RAs).3 IVIG are generally reserved
for ITP patients who require a rapid increase in platelet
count. A disadvantage of IVIG is that they are not curative
and often poorly tolerated.3 As IVIG inhibit the phagocytic
capabilities of macrophages,4 treatment with IVIG in an early
stage of COVID-19 may be successful.5 Additionally, some
COVID-19 patients who suffered deterioration of clinical
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symptoms have been salvaged by IVIG treatment.6 IVIG was
chosen in patient 1 because of active bleeding and the rela-
tive contraindication of glucocorticoid treatment, which may
interfere with the somatostatin analogue therapy for the
NET, and in patient 2 because of failure of dexamethasone
treatment. Glucocorticoids comprise the primary treatment
of ITP.3 However, glucocorticoids are considered harmful for
patients with COVID-19 infection as they inhibit immune
responses and clearance of the SARS-COV-2 virus.7 Patient 2
received treatment with dexamethasone because she had no
symptoms of the COVID-19 infection for over a week. She
received a short course of high-dose dexamethasone rather
than a longer period of prednisone which is associated with
significant toxicities and a longer time to response.8 COVID-
19 infection may be accompanied by thrombocytopenia as a
result of DIC, which is associated with a strongly increased
risk of thromboembolism reported in 30% of the patients.9
As treatment with TPO-RA has shown in selected cases to
increase the risk of venous thromboembolism,10 it should be
used with caution in COVID-19 infection.
Table I. Patient characteristics of the three patients with COVID-19-associated immune thrombocytopenia.
Patient 1 Patient 2 Patient 3 Reference range
Age 59 66 67
Sex Male Female Male
Haemoglobin level (mmol/l) 83 80 93 86–105
Platelet count (9109/l) <3 2 338 150–370
Leucocyte count (9109/l) 39 58 112 35–10
Lymphocyte count (9109/l) 04 07 086 05–5
PT (s) 125 104 n.d. 109–133
APTT (s) 220 228 n.d. 220–320
D-dimer (lg/l) n.d. 1411 >35 200 0–500
Autoantibodies
GPIb Positive Negative n.d.
GPIIBIIa Positive Negative n.d.
GPV Positive Negative n.d.
Anti-cardiolipin antibodies n.d. Negative n.d.
Anti-beta-2-glycoprotein I n.d. Negative n.d.
Thrombopoietin (Units/ml) 56 100 n.d. 4–32
Virus serology
HIV Negative Negative n.d.
Hepatitis B and C Negative Negative n.d.
EBV Negative Negative n.d.
Parvo B19 virus Negative n.d. n.d.
CMV virus Negative n.d. 288/P
Helicobacter pylori Negative Negative n.d.
Interleukin-6 (ng/l) 19 3 270 <10
GP, glycoprotein; HIV, human immunodeficiency virus; EBV, Epstein–Barr virus; CMV, cytomegalovirus; n.d., not done.
Fig 1. The course of platelet counts of three patients (A-C) with COVID-19-associated immune thrombocytopenia. Patient 3 (C) died at day 13
because of an intracerebral bleeding. IVIG, intravenous immunoglobulins (1 g/kg on two consecutive days); PC, platelet concentrate transfusion;
DEX, 4 days 40 mg/day treatment with dexamethasone.
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In conclusion, this is the first case series of three patients
with a COVID-19-associated ITP. It is important to be aware
of this severe complication of a COVID-19 infection and
should be diagnosed and treated immediately. Failure to
recognise it on time may ultimately lead to fatal complica-
tions, as shown in one of our patients. Choice of treatment
of ITP should be based on balancing the risk of bleeding due
to ITP versus potential deterioration of COVID-19 infection
due to immunosuppressive therapy.
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Fig S1. (A) Bone marrow aspirate with May–Gr€unwald
Giemsa staining and at 6139 magnification. Normal
cellularity and an increase in ther amount of megakaryocytes
were found.
Fig S1. (B) Bone marrow trephine biopsy (PAS staining,
original object lens magnification 209) with a cluster of
three megakaryocytes (Meg). The number is increased; how-
ever, they appear morphologically normal. Note the erythro-
poiesis organised in regularly spaced erythrons (E) and the
mestastasis (M) of the neuroendocrine tumour. Although
minimal localisation of NET cells was found in the bone
marrow, no signs of dysplasia were found. Additionally, with
a normal haemoglobin value and leucocyte count we
assumed localisation of the NET cells in the bone marrow
could not explain the low platelet count, making the diagno-
sis of ITP more likely.
Fig S2. Petechiae on the left leg of patient 2.
References
1. Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, et al. Association
between platelet parameters and mortality in coronavirus disease 2019: ret-
rospective cohort study. Platelets. 2020;209:1–7.
2. Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andres E. Immune thrombo-
cytopenic purpura in a patient with COVID-19. N Engl J Med. 2020;382
(18):e43.
3. Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med.
2019;381:945–55.
4. Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen
AJG. Emerging concepts in immune thrombocytopenia. Front Immunol.
2018;9:880.
5. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose
intravenous immunoglobulin as a therapeutic option for deteriorating
patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7:
ofaa102.
6. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular
intravenous immunoglobulin therapy on prognosis of severe pneumonia
in patients with COVID-19. J Infect. 2020. https://doi.org/10.1016/j.jinf.
2020.03.044
7. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:
473–5.
8. Wang L, Xu L, Hao H, Jansen AJG, Liu G, Li H, et al. First line treatment
of adult patients with primary immune thrombocytopenia: a real-world
study. Platelets. 2020;31:55–61.
9. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers
DAMPJ, Kant KM, et al. Incidence of thrombotic complications in criti-
cally ill ICU patients with COVID-19. Thromb Res. 2020. pii: S0049–3848
(20)30120–1. https://doi.org/10.1016/j.thromres.2020.04.013.
10. Jansen AJG, Swart RM, te Boekhorst PAW. Thrombopoietin-receptor ago-
nists for immune thrombocytopenia. N Engl J Med. 2011;365:2240–1.
Correspondence
ª 2020 British Society for Haematology and John Wiley & Sons Ltd 3
